Sökning: id:"swepub:oai:DiVA.org:uu-201807" >
Characterization of...
Characterization of anti-natalizumab antibodies in multiple sclerosis patients
-
- Lundkvist, M. (författare)
- Karolinska Institutet
-
- Engdahl, E. (författare)
- Karolinska Institutet
-
- Holmen, C. (författare)
- Karolinska Institutet
-
visa fler...
-
- Moverare, Robert (författare)
- Uppsala universitet,Lungmedicin och allergologi
-
- Olsson, T. (författare)
- Karolinska Institutet
-
- Hillert, J. (författare)
- Karolinska Institutet
-
- Fogdell-Hahn, A. (författare)
- Karolinska Institutet
-
visa färre...
-
(creator_code:org_t)
- 2012-10-08
- 2013
- Engelska.
-
Ingår i: Multiple Sclerosis Journal. - : SAGE Publications. - 1352-4585 .- 1477-0970. ; 19:6, s. 757-764
- Relaterad länk:
-
https://urn.kb.se/re...
-
visa fler...
-
https://doi.org/10.1...
-
http://kipublication...
-
visa färre...
Abstract
Ämnesord
Stäng
- Background: A small proportion of multiple sclerosis (MS) patients treated with natalizumab develop anti-drug antibodies. Objective: The objective of this paper is to characterize the anti-natalizumab antibody response and to investigate differences between persistently and transiently antibody-positive patients. Methods: Screening for anti-natalizumab antibodies was performed using a standardized bridging ELISA. Antibody-positive samples were further analyzed for IgM and IgG1-4 antibodies using ELISA and ImmunoCAP (R). Results: Anti-natalizumab antibodies developed in 57 of 1379 (4.1%) treated patients after a median treatment duration of three months. Of the positive patients, 20 (35%) patients reverted to negative, 19 (33%) patients were confirmed persistently positive and 18 (32%) patients were unconfirmed positive. Significantly higher anti-natalizumab antibody levels were detected in persistently compared to transiently positive patients. A cutoff value predicting persistence of antibodies could be determined with a sensitivity of 0.84 and a specificity of 0.80. IgM and IgG4 antibody levels were significantly higher in persistently compared to transiently positive patients, and IgG1, IgG2 and IgG4 increased significantly over time. Conclusions: The level of total anti-natalizumab antibodies in a first positive sample can be used to predict patients at risk for persisting antibody positivity. However, neither IgM nor IgG1-4 antibodies could be used to discriminate between transiently and persistently positive patients.
Nyckelord
- Anti-drug antibody
- natalizumab
- multiple sclerosis
Publikations- och innehållstyp
- ref (ämneskategori)
- art (ämneskategori)
Hitta via bibliotek
Till lärosätets databas